Anti-CD16-anti-CD30 monoclonal antibody

Drug Profile

Anti-CD16-anti-CD30 monoclonal antibody

Alternative Names: Anti-CD16-anti-CD30 bispecific monoclonal antibody; Anti-CD30-anti-CD16 bispecific monoclonal antibody; Anti-CD30-anti-CD16 monoclonal antibody

Latest Information Update: 22 Mar 2007

Price : $50

At a glance

  • Originator Biotest
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease

Most Recent Events

  • 22 Mar 2007 Discontinued - Phase-II for Hodgkin's disease in Germany (IV-infusion)
  • 14 Sep 2000 A phase II study has been added to the Cancer therapeutic trials and pharmacodynamics sections
  • 28 May 1997 A study has been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top